Organisation paid for research Program year 2024 Source: CMS Open Payments

Futuro Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$3,966,125

34 payments

Through program year 2024, Futuro Clinical Trials is reported as receiving $3,966,125 in research payments, across 34 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2024	Research	$663,371	30
2023	Research	$3,263,937	2
2022	Research	$38,818	2

Breakdown

Who paid Research payments · program years 2022–2024

Vertex Pharmaceuticals Incorporated $3,812,763 6 payments
GlaxoSmithKline, LLC. $153,363 28 payments

Studies the money was for Research payments · program years 2022–2024

A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy $2,075,428 3 payments
A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain $1,737,334 3 payments
A Multicenter Randomized, Double-Blind, Placebo-Controlled Phase 2 Stu $153,363 28 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.